Kentucky Senate Republicans had a political hot potato in their possession. Late in the 2024 General Assembly, some in the caucus were clamoring to pass a bill banning diversity, equity and inclusion ...

Kentucky Senate President Robert Stivers speaks with a crowd of reporters after the first gavel of the legislative session, outlining priorities and challenges ahead Unprecedented and unconstitutional ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

This is read by an automated voice. Please report any issues or inconsistencies here. On a nippy Monday night at the Zebulon in Frogtown, a man wearing a Jason Voorhees T-shirt steps onto a ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

This is read by an automated voice. Please report any issues or inconsistencies here. Hungarian Nobel Prize laureate László Krasznahorkai delivered a rare lecture in Stockholm, presenting ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...